Imaging With a New Agent That Finds a Cancer Protein Called HER2
Status:
Completed
Trial end date:
2018-04-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds
HER2 proteins can be used to take pictures of HER2-positive cancer.